Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of AGN-151586 for the Treatment of Glabellar Lines in Toxin-Naïve Subjects

NCT05248880 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05248880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05248880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of AGN-151586 for the Treatment of Glabellar Lines in Toxin-Naïve Subjects
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
March 8, 2022
Completion date
February 1, 2023
Enrollment
309 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar lines